Ibrutinib
Small molecule
Evidence outlook
Approved: Chronic Lymphocytic Leukemia, Graft-versus-Host Disease, Chronic Graft-versus-Host Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Mantle Cell Lymphoma · Phase 3Diffuse Large B-Cell Lymphoma · Phase 3
Also approved (4)
- Adult patients with Waldenström's macroglobulinemia (WM)
- Treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
- IMBRUVICA (ibrutinib) is indicated: • for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion. Clinical effectiveness of IMBRUVICA in previously untreated adult patients with CLL with 17p deletion is based on the benefit observed in patients with CLL with 17p deletion who have received at least one prior therapy. Clinical trial data in previously untreated patients with CLL with 17p deletion are very limited. • in combination with obinutuzumab for the treatment of adult patients with previously untreated CLL,...
- Imbruvica in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (IMBRUVICA + R-CHOP) alternating with R-DHAP (or R-DHAOx) without Imbruvica, followed by Imbruvica monotherapy, is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT).Imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory MCL.Imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RESONATE NCT01578707 · Chronic Lymphocytic Leukemia This was a large randomized, active-controlled trial of ibrutinib versus ofatumumab, with progression-free survival as a clinical primary endpoint and a statistically significant favorable result for ibrutinib. However, treatment was open-label rather than double-blinded, so the evidence is graded moderate despite the strong primary result. Registry: NCT01578707 | 3 | PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013 (Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.) 2013-11 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
View 5 more trials
NCT01722487 NCT01722487 · Chronic Lymphocytic Leukemia The trial was randomized and actively controlled, with 136 participants receiving ibrutinib and 133 receiving chlorambucil, and its clinical primary endpoint of progression-free survival was significantly better with ibrutinib. However, treatment was open-label rather than double-blinded, limiting the strength of the evidence despite the favorable result. Registry: NCT01722487 | 3 | PFS (Progression Free Survival) (Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.) 2015-05 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT02264574 NCT02264574 · Chronic Lymphocytic Leukemia The trial was randomized and actively controlled, with 113 participants receiving ibrutinib plus obinutuzumab and 116 receiving chlorambucil plus obinutuzumab, but treatment was open-label rather than blinded. The primary progression-free survival endpoint was met, with 30-month progression-free survival of 78.5% versus 31.1% (p<0.0001) and 48-month progression-free survival of 74.0% versus 22.0% (p<0.0001), supporting moderate evidence despite the lack of masking. Registry: NCT02264574 | 3 | Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30 (Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).); Final Analysis: PFS Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48 (Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).) 2018-03-26 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT01611090 NCT01611090 · Chronic Lymphocytic Leukemia The trial was randomized, placebo-controlled and blinded to patients, doctors and investigators, and it clearly met its primary endpoint: progression-free survival, judged by an independent review committee, was much longer with ibrutinib (hazard ratio 0.229, p<0.0001). A power calculation was reported, and the trial randomized 578 patients against a planned figure of approximately 580. Registry: NCT01611090 | 3 | Progression-free Survival (PFS) (Up to 5 years) 2019-01-23 | Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) | Reliable signal | link ↗ |
NCT01105247 NCT01105247 · Chronic Lymphocytic Leukemia The study was nonrandomized, unblinded, and single-arm, with no placebo or active comparator, so its safety findings cannot establish comparative efficacy or safety. The primary endpoint was safety rather than a comparative clinical efficacy outcome, and no formal primary endpoint comparison was applicable. Registry: NCT01105247 | 1/2 | Number of Participants With Treatment Emergent Adverse Events (AEs) (From first dose to within 30 days of last dose of PCI-32765) 2012-12 | Number of Participants With Treatment Emergent Adverse Events (AEs) (From first dose to within 30 days of last dose of PCI-32765): PCI-32765 116 Participants | Food Effect 11 Participants | Weak signal | link ↗ |
NCT02048813 NCT02048813 · Chronic Lymphocytic Leukemia The trial randomly assigned 529 participants to ibrutinib plus rituximab or active comparator therapy, with no masking. Its objective primary endpoint, 3-year progression-free survival, favored the ibrutinib arm significantly (89.4% vs 72.9%; hazard ratio 0.35, p<.001), but the open-label design and absence of a reported power calculation limit the evidence grade. Registry: NCT02048813 | 3 | Progression-free Survival (PFS) Rate at 3 Years (Assessed every 3 months until progression up to 4 years and 8 months) 2018-10-24 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (31)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (152)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (54)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (88)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (9)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Appears in other studies (6)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other BTK drugs
Acalabrutinib, Pirtobrutinib, rilzabrutinib, zanubrutinib. Compare all 5 BTK drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Chronic Graft-versus-Host Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ibrutinib: this drug | Approved | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Axatilimab | Approved | Monoclonal antibody | CSF-1R | Weak signal | Featured results are non-efficacy only in this race | |
| Belumosudil | Approved | Small molecule | Rho-associated kinase (ROCK, pan) | Weak signal | NCT03640481: Overall Response Rate (ORR) (From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)): Adult Arm A: Belumosudil 200 mg QD 74 Percentage of participants | Adult Arm B: Belumosudil 200 mg BID 76 Percentage of participants | Adolescent Arm A: Belumosudil 200 mg QD 50 Percentage of participants | Adolescent Arm B: Belumosudil 200 mg BID 100 Percentage of participants | |
| Rilzabrutinib | Approved(overall) | Small molecule | BTK | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Jakafi) | Approved | Small molecule | JAK1/2 | Partial signal | NCT03112603: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit (Cycle 7 Day 1 (each cycle was comprised of 4 weeks)): Ruxolitinib 49.7 percentage of participants (95% CI 41.8 to 57.6) | Best Available Therapy 25.6 percentage of participants (95% CI 19.1 to 33) |
Upcoming events
(46 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ibrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.